30 December 2025 in Journal of Neuromuscular Diseases
Background: The clinical course of Spinal Muscular Atrophy (SMA) has been transformed by new disease-modifying therapies (DMT). Before DMT, the clinical course of SMA was marked by an inflection point between developmental improvement and degenerative functional losses. The well-established SMA classification by “type” was based upon the age and functional level at which this inflection point manifested. Following DMT, the natural history of SMA has evolved. The evolution of the SMA clinical course following DMT thus necessitates an updated means to characterize individuals with SMA. Objective: To address both clinical and research needs, an updated assessment should target meaningful function; apply broadly across the range of SMA; maximize the granularity of functional tiers with minimal compromise of reliability; require minimal or no specific training; and be validated with measurable consistency between both naïve and experienced clinicians, and between these clinicians and members of the SMA community. Methods/Design: Development of the Functional Ability Scale for Evolving SMA (EVOLVE-SMA) proceeded as an iterative scale creation and refinement process using retrospective cohorts (for design, reliability, and validity) followed by prospective assessments of real-world feasibility and reliability. Results: Excellent interrater reliability (ICC >0.9, p < 0.001) was established between expert and novice clinicians (physician and physical therapist) and clinicians versus SMA community members. Conclusions: EVOLVE-SMA is a tiered evaluation of function applicable to the new DMT-treated era of SMA. It is a simple, granular, and reliable means to assess meaningful functions that will have value to research, resource allocation, and individual clinical care.
1 September 2026 in American Journal of Physical Medicine & Rehabilitation
It is unexpected when initial certification examinees pass the American Board of Physical Medicine and Rehabilitation (ABPMR) Part I Examination with a top score and subsequently fail the Part II Examination. This study aims to determine individual and residency program factors associated with this outcome. A retrospective, observational review of ABPMR data between 1999 and 2025 identified 161 individuals (1.6% of all examinees) who passed Part I with top quartile performance but subsequently failed one or more attempt at Part II. Multinomial logistic regression models demonstrated a lower odds ratio for Part II failure among female physicians (OR=0.60, P =0.016) and those enrolled in fellowship training (OR=0.53, P =0.006). A higher odds ratio was found for physicians aged >40 years (OR=3.80, P <0.001), non-white ethnicity (OR=1.80, P =0.004), and those who completed newer (<10 years, OR=3.13, P =0.026) and smaller (2-4 and 5-7 residents per year, OR=1.98 and 2.13, P =0.009 and 0.001) residency programs. Awareness of this potential outcome should prompt rigorous preparation for the Part II Examination, even for the highest performing Part I examinees.